

DAFTAR PUSTAKA

- Agarwal, R. (2021). Pathogenesis of Diabetic Nephropathy. In Chronic Kidney Disease and Type 2 Diabetes. American Diabetes Association. <http://www.ncbi.nlm.nih.gov/books/NBK571720/>
- Ali, H. et al. (2022) 'Association of significantly elevated plasma levels of NGAL and IGFBP4 in patients with diabetic nephropathy', BMC Nephrology, 23(1), pp. 1–10. doi: 10.1186/s12882-022-02692-z.
- Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 12(12), 2032–2045. <https://doi.org/10.2215/CJN.11491116>
- American Diabetes Association. (2013). Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 37(Supplement_1), S81–S90. <https://doi.org/10.2337/dc14-S081>
- Aslanhan, E. et al. (2019) 'Association of neutrophil-gelatinase-associated lipocalin with microvascular complications in patients with type 2 diabetes: A cross-sectional study', Cardiovascular Endocrinology and Metabolism, 8(3), pp. 82–87. doi: 10.1097/XCE.0000000000000180.
- Azmi, S., Petropoulos, I. N., Ferdousi, M., Ponirakis, G., Alam, U., & Malik, R. A. (2019). An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy. F1000Research, 8, F1000 Faculty Rev-186. <https://doi.org/10.12688/f1000research.17118.1>
- Banday, M. Z., Sameer, A. S., & Nissar, S. (2020). Pathophysiology of diabetes: An overview. Avicenna Journal of Medicine, 10(4), 174–188. https://doi.org/10.4103/ajm.ajm_53_20
- Bertocchio, J.-P., Warnock, D. G., & Jaisser, F. (2011). Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease. Kidney International, 79(10), 1051–1060. <https://doi.org/10.1038/ki.2011.48>



- Bolignano, D. et al. (2008) 'Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Marker of Kidney Damage', *American Journal of Kidney Diseases*, 52(3), pp. 595–605. doi: 10.1053/j.ajkd.2008.01.020.
- Bolignano, D. et al. (2009) 'Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients', *Kidney and Blood Pressure Research*, 32(2), pp. 91–98. doi: 10.1159/000209379.
- Bolignano, D., Lacquaniti, A., Coppolino, G., Donato, V., Fazio, M. R., Nicocia, G., & Buemi, M. (2009). Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. *Kidney & Blood Pressure Research*, 32(2), 91–98. <https://doi.org/10.1159/000209379>
- Cai, L., Rubin, J., Han, W., Venge, P., & Xu, S. (2010). The origin of multiple molecular forms in urine of HNL/NGAL. *Clinical Journal of the American Society of Nephrology: CJASN*, 5(12), 2229–2235. <https://doi.org/10.2215/CJN.00980110>
- Cavalli, E., Mammana, S., Nicoletti, F., Bramanti, P., & Mazzon, E. (2019). The neuropathic pain: An overview of the current treatment and future therapeutic approaches. *International Journal of Immunopathology and Pharmacology*, 33, 2058738419838383. <https://doi.org/10.1177/2058738419838383>
- Chakraborty, S., Kaur, S., Tong, Z., Batra, S. K., Guha, S., Chakraborty, S., Kaur, S., Tong, Z., Batra, S. K., & Guha, S. (2011). Neutrophil Gelatinase Associated Lipocalin: Structure, Function and Role in Human Pathogenesis. In *Acute Phase Proteins—Regulation and Functions of Acute Phase Proteins*. IntechOpen. <https://doi.org/10.5772/18755>
- Dahiva, K., Prashant, P., Dhankhar, R., Dhankhar, K., Kumar, S., & Vashist, . (2023). Lipocalin-2 as a biomarker for diabetic nephropathy. *World Journal of Meta-Analysis*, 11(4), 92–101. [tps://doi.org/10.13105/wjma.v11.i4.92](https://doi.org/10.13105/wjma.v11.i4.92)



de Boer, I. H., Rue, T. C., Cleary, P. A., Lachin, J. M., Molitch, M. E., Steffes, M. W., Sun, W., Zinman, B., Brunzell, J. D., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, White, N. H., Danis, R. P., Davis, M. D., Hainsworth, D., Hubbard, L. D., & Nathan, D. M. (2011). Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: An analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. *Archives of Internal Medicine*, 171(5), 412–420. <https://doi.org/10.1001/archinternmed.2011.16>

de Boer, I. H., Sibley, S. D., Kestenbaum, B., Sampson, J. N., Young, B., Cleary, P. A., Steffes, M. W., Weiss, N. S., Brunzell, J. D., & Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. (2007). Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. *Journal of the American Society of Nephrology: JASN*, 18(1), 235–243. <https://doi.org/10.1681/ASN.2006040394>

Demeditec Diagnostics, G. (2022). IGF-I ELISA - DEE020—Demeditec Diagnostics GmbH.

Diabetes. (n.d.). Retrieved June 12, 2023, from <https://www.who.int/news-room/fact-sheets/detail/diabetes>

Diabetic Nephropathy: Practice Essentials, Pathophysiology, Etiology. (2023). <https://emedicine.medscape.com/article/238946-overview#a5>

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Rohalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., ... on behalf of the American Diabetes Association. (2022). 2. Classification and diagnosis of Diabetes: Standards of Care in Diabetes—2023.



Diabetes Care, 46(Supplement_1), S19–S40.
<https://doi.org/10.2337/dc23-S002>

Fan, J.-Z., & Wang, R. (2018). Non-diabetic renal disease in patients with type 2 diabetes: A single centre study. *Internal Medicine Journal*, 48(4), 451–456. <https://doi.org/10.1111/imj.13708>

Fiseha, T. (2015). Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients. *Biomarker Research*, 3, 16. <https://doi.org/10.1186/s40364-015-0042-3>

Flower, D. R., North, A. C., & Sansom, C. E. (2000). The lipocalin protein family: Structural and sequence overview. *Biochimica Et Biophysica Acta*, 1482(1–2), 9–24. [https://doi.org/10.1016/s0167-4838\(00\)00148-5](https://doi.org/10.1016/s0167-4838(00)00148-5)

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., Garber, J. R., Garvey, W. T., Grunberger, G., Handelsman, Y., Hirsch, I. B., Jellinger, P. S., McGill, J. B., Mechanick, J. I., Rosenblit, P. D., & Umpierrez, G. E. (2018). Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. *Endocrine Practice*, 24(1), 91–121. <https://doi.org/10.4158/CS-2017-0153>

Ghaderian, S. B., Hayati, F., Shayanpour, S., & Beladi Mousavi, S. S. (2015). Diabetes and end-stage renal disease; a review article on new concepts. *Journal of Renal Injury Prevention*, 4(2), 28–33. <https://doi.org/10.12861/jrip.2015.07>

Gnudi, L. (2016). Angiopoietins and diabetic nephropathy. *Diabetologia*, 59, 1616–1620. <https://doi.org/10.1007/s00125-016-3995-3>

J. H., Willie, S. T., Armen, R. S., Bratt, T., Borregaard, N., & Strong, A. K. (2000). Ligand preference inferred from the structure of



neutrophil gelatinase associated lipocalin. *Biochemistry*, 39(8), 1935–1941. <https://doi.org/10.1021/bi992215v>

Hafez, M. H. et al. (2015) 'Detection of an earlier tubulopathy in diabetic nephropathy among children with normoalbuminuria', *Iranian Journal of Kidney Diseases*, 9(2), pp. 126–131.

Hammes, H.-P. (2018). Diabetic retinopathy: Hyperglycaemia, oxidative stress and beyond. *Diabetologia*, 61(1), 29–38. <https://doi.org/10.1007/s00125-017-4435-8>

Horiba. (2006). Glucose HK-CP. In *Diagnostic Reagent for Quantitative In Vitro Determination of Glucose*. Horiba.

Hosny, S. S. et al. (2018) 'Urinary neutrophil gelatinase-associated lipocalin in type 2 diabetes: Relation to nephropathy and retinopathy', *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 12(6), pp. 1019–1024. doi: 10.1016/j.dsx.2018.06.017.

Huang, D., Refaat, M., Mohammedi, K., Jayyousi, A., Al Suwaidi, J., & Abi Khalil, C. (2017). Macrovascular Complications in Patients with Diabetes and Prediabetes. *BioMed Research International*, 2017, e7839101. <https://doi.org/10.1155/2017/7839101>

IDF_Atlas_10th_Edition_2021.pdf. (n.d.). Retrieved June 15, 2023, from https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf

Infodatin 2020 Diabetes Melitus.pdf. (n.d.). Retrieved June 15, 2023, from <https://www.kemkes.go.id/downloads/resources/download/pusdatin/infodatin/Infodatin%202020%20Diabetes%20Melitus.pdf>

Jha, J. C., Jandeleit-Dahm, K. A. M., & Cooper, M. E. (2014). New Insights Into the Use of Biomarkers of Diabetic Nephropathy. *Advances in Chronic Kidney Disease*, 21(3), 318–326. <https://doi.org/10.1053/j.ackd.2014.03.008>

G. J., & Hansen, M. P. (2016). Type 1 diabetes associated autoimmunity. *Autoimmunity Reviews*, 15(7), 644–648. [tps://doi.org/10.1016/j.autrev.2016.02.017](https://doi.org/10.1016/j.autrev.2016.02.017)



- Kahdem, A. et al. (2017) 'Neutrophil gelatinase associated lipocalin (NGAL) in early detection of nephropathy in type 2 diabetic Iraqi patients', *Journal of the Faculty of Medicine-Baghdad*, 59(1), pp. 74–78. doi: 10.32007/med.1936/jfacmedbagdad.v59i1.15.
- Kaul, A. et al. (2018) 'Neutrophil gelatinase-associated lipocalin: As a predictor of early diabetic nephropathy in Type 2 diabetes mellitus', *Indian Journal of Nephrology*, 28(1), p. 53. doi: 10.4103/ijn.IJN_96_17.
- Kaul, A., Behera, M. R., Rai, M. K., Mishra, P., Bhaduarua, D. S., Yadav, S., Agarwal, V., Karoli, R., Prasad, N., Gupta, A., & Sharma, R. K. (2018). Neutrophil Gelatinase-associated Lipocalin: As a Predictor of Early Diabetic Nephropathy in Type 2 Diabetes Mellitus. *Indian Journal of Nephrology*, 28(1), 53–60. https://doi.org/10.4103/ijn.IJN_96_17
- Kern, E. O., Erhard, P., Sun, W., Genuth, S., & Weiss, M. F. (2010). Early Urinary Markers of Diabetic Kidney Disease: A Nested Case-Control Study From the Diabetes Control and Complications Trial (DCCT). *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, 55(5), 824–834. <https://doi.org/10.1053/j.ajkd.2009.11.009>
- Klessens, C. Q. F., Woutman, T. D., Veraar, K. A. M., Zandbergen, M., Valk, E. J. J., Rotmans, J. I., Wolterbeek, R., Bruijn, J. A., & Bajema, I. M. (2016). An autopsy study suggests that diabetic nephropathy is underdiagnosed. *Kidney International*, 90(1), 149–156. <https://doi.org/10.1016/j.kint.2016.01.023>
- Kühl, C. (1998). Etiology and pathogenesis of gestational diabetes. *Diabetes Care*, 21 Suppl 2, B19-26.
- Levey, A. S., Becker, C., & Inker, L. A. (2015). Glomerular Filtration Rate and Albuminuria for Detection and Staging of Acute and Chronic Kidney Disease in Adults: A Systematic Review. *JAMA*, 313(8), 837–846. <https://doi.org/10.1001/jama.2015.0602>



- Liao, D. et al. (2019) 'Cigarette smoking as a risk factor for diabetic nephropathy: A systematic review and meta-analysis of prospective cohort studies', PLoS ONE, 14(2), pp. 1–15. doi: 10.1371/journal.pone.0210213.
- Mallbris, L., O'Brien, K. P., Hulthén, A., Sandstedt, B., Cowland, J. B., Borregaard, N., & Ståhle-Bäckdahl, M. (2002). Neutrophil gelatinase-associated lipocalin is a marker for dysregulated keratinocyte differentiation in human skin. *Experimental Dermatology*, 11(6), 584–591. <https://doi.org/10.1034/j.1600-0625.2002.110611.x>
- Mårtensson, J., & Bellomo, R. (2014). The Rise and Fall of NGAL in Acute Kidney Injury. *Blood Purification*, 37(4), 304–310. <https://doi.org/10.1159/000364937>
- Mori, K., & Nakao, K. (2007). Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. *Kidney International*, 71(10), 967–970. <https://doi.org/10.1038/sj.ki.5002165>
- Mori, K., Lee, H. T., Rapoport, D., Drexler, I. R., Foster, K., Yang, J., Schmidt-Ott, K. M., Chen, X., Li, J. Y., Weiss, S., Mishra, J., Cheema, F. H., Markowitz, G., Suganami, T., Sawai, K., Mukoyama, M., Kunis, C., D'Agati, V., Devarajan, P., & Barasch, J. (2005). Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. *The Journal of Clinical Investigation*, 115(3), 610–621. <https://doi.org/10.1172/JCI23056>
- Nguyen, D., Ping, F., Mu, W., Hill, P., Atkins, R. C., & Chadban, S. J. (2006). Macrophage accumulation in human progressive diabetic nephropathy. *Nephrology (Carlton, Vic.)*, 11(3), 226–231. <https://doi.org/10.1111/j.1440-1797.2006.00576.x>
- Nielsen, S. E. et al. (2012) 'Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients', *Diabetes research and Clinical Practice*, 97(1), pp. 71–76. doi: 10.1016/j.diabres.2012.02.007.



- Noctor, E., Crowe, C., Carmody, L. A., Saunders, J. A., Kirwan, B., O'Dea, A., Gillespie, P., Glynn, L. G., McGuire, B. E., O'Neill, C., O'Shea, P. M., Dunne, F. P., & ATLANTIC-DIP investigators. (2016). Abnormal glucose tolerance post-gestational diabetes mellitus as defined by the International Association of Diabetes and Pregnancy Study Groups criteria. *European Journal of Endocrinology*, 175(4), 287–297. <https://doi.org/10.1530/EJE-15-1260>
- Ntrinas, T., Papasotiriou, M., Balta, L., Kalavrizioti, D., Vamvakas, S., Papachristou, E., & Goumenos, D. S. (2019). Biomarkers in Progressive Chronic Kidney Disease. Still a Long Way to Go. *PRILOZI*, 40(3), 27–39. <https://doi.org/doi:10.2478/prilozi-2020-0002>
- Papadopoulou-Marketou, N. et al. (2015) 'NGAL and cystatin C: Two possible early markers of diabetic nephropathy in young patients with type 1 diabetes mellitus: One year follow up', *Hormones*, 14(2), pp. 232–240. doi: 10.14310/horm.2002.1520.
- Papadopoulou-Marketou, N., Kanaka-Gantenbein, C., Marketos, N., Chrousos, G. P., & Papassotiriou, I. (2017). Biomarkers of diabetic nephropathy: A 2017 update. *Critical Reviews in Clinical Laboratory Sciences*, 54(5), 326–342. <https://doi.org/10.1080/10408363.2017.1377682>
- Papadopoulou-Marketou, N., Margeli, A., Papassotiriou, I., Chrousos, G. P., Kanaka-Gantenbein, C., & Wahlberg, J. (2017). NGAL as an Early Predictive Marker of Diabetic Nephropathy in Children and Young Adults with Type 1 Diabetes Mellitus. *Journal of Diabetes Research*, 2017, e7526919. <https://doi.org/10.1155/2017/7526919>
- Parmar, T., Parmar, V. M., Perusek, L., Georges, A., Takahashi, M., Crabb, J. W., & Maeda, A. (2018). Lipocalin 2 Plays an Important Role in Regulating Inflammation in Retinal Degeneration. *The Journal of Immunology*, 200(9), 3128–3141. <https://doi.org/10.4049/jimmunol.1701573>



Pavkov, M. E., Bennett, P. H., Knowler, W. C., Krakoff, J., Sievers, M. L., & Nelson, R. G. (2006). Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. *JAMA*, 296(4), 421–426. <https://doi.org/10.1001/jama.296.4.421>

Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di INDONESIA - 2021. (2021).

Perkins, B. A., Ficociello, L. H., Silva, K. H., Finkelstein, D. M., Warram, J. H., & Krolewski, A. S. (2003). Regression of microalbuminuria in type 1 diabetes. *The New England Journal of Medicine*, 348(23), 2285–2293. <https://doi.org/10.1056/NEJMoa021835>

Prasad, R. M., Bali, A., & Tikaria, R. (2023). Microalbuminuria. In StatPearls. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK563255/>

Rahimi, Z. (2016). The Role of Renin Angiotensin Aldosterone System Genes in Diabetic Nephropathy. *Canadian Journal of Diabetes*, 40(2), 178–183. <https://doi.org/10.1016/j.jcjd.2015.08.016>

Rajaei, E., Jalali, M. T., Shahrabi, S., Asnafi, A. A., & Pezeshki, S. M. S. (2019). HLAs in Autoimmune Diseases: Dependable Diagnostic Biomarkers? *Current Rheumatology Reviews*, 15(4), 269–276. <https://doi.org/10.2174/1573397115666190115143226>

Rapa', Y., Kurniawan, L. B., Nurulita, A., & Mangarengi, F. (2022). Analysis of Neutrophil Gelatinase-Associated Lipocalin in Type 2 Diabetes Mellitus Patients. *INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY*, 28(2), 185–190. <https://doi.org/10.24293/ijcpml.v28i2.1807>

Reddy, S. S. K., & Tan, M. (2020). Diabetes mellitus and its many complications. In *Diabetes Mellitus* (pp. 1–18). Elsevier. <https://doi.org/10.1016/B978-0-12-820605-8.00001-2>



u, V., Lasseur, C., Raffaitin, C., Beauvieux, M.-C., Barthe, N., hauveau, P., Combe, C., & Gin, H. (2007). Normoalbuminuric renal-

- insufficient diabetic patients: A lower-risk group. *Diabetes Care*, 30(8), 2034–2039. <https://doi.org/10.2337/dc07-0140>
- Sapra, A., & Bhandari, P. (2023). Diabetes. In StatPearls. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK551501/>
- Satirapoj, B. (2018). Tubulointerstitial Biomarkers for Diabetic Nephropathy. *Journal of Diabetes Research*, 2018, 1–6. <https://doi.org/10.1155/2018/2852398>
- Schleicher, E. D., & Weigert, C. (2000). Role of the hexosamine biosynthetic pathway in diabetic nephropathy. *Kidney International. Supplement*, 77, S13-18. <https://doi.org/10.1046/j.1523-1755.2000.07703.x>
- Sheetz, M. J., & King, G. L. (2002). Molecular understanding of hyperglycemia's adverse effects for diabetic complications. *JAMA*, 288(20), 2579–2588. <https://doi.org/10.1001/jama.288.20.2579>
- Singer, E., Markó, L., Paragas, N., Barasch, J., Dragun, D., Müller, D. N., Budde, K., & Schmidt-Ott, K. M. (2013). Neutrophil gelatinase-associated lipocalin: Pathophysiology and clinical applications. *Acta Physiologica*, 207(4), 663–672. <https://doi.org/10.1111/apha.12054>
- Singh, D. K., Winocour, P., Summerhayes, B., Viljoen, A., Sivakumar, G., & Farrington, K. (2009). Are low erythropoietin and 1,25-dihydroxyvitamin D levels indicative of tubulo-interstitial dysfunction in diabetes without persistent microalbuminuria? *Diabetes Research and Clinical Practice*, 85(3), 258–264. <https://doi.org/10.1016/j.diabres.2009.06.022>
- Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., McElvaine, A. T., Palmer, J. P., Pugliese, A., Schatz, D. A., Sosenko, J. M., Wilding, J. P. H., & Ratner, R. E. (2016). Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. *Diabetes*, 66(2), 241–255. <https://doi.org/10.2337/db16-0806>
- , P. E. (2013). Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global



Outcomes 2012 Clinical Practice Guideline. *Annals of Internal Medicine*, 158(11), 825. <https://doi.org/10.7326/0003-4819-158-11-201306040-00007>

Tesch, G. H. (2010). Macrophages and diabetic nephropathy. *Seminars in Nephrology*, 30(3), 290–301. <https://doi.org/10.1016/j.semnephrol.2010.03.007>

Thrallkill, K. M. et al. (2010) 'Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus', *Endocrine*, 37(2), pp. 336–343. doi: 10.1007/s12020-010-9308-6.

Tong, Z., Kunnumakkara, A. B., Wang, H., Matsuo, Y., Diagaradjane, P., Harikumar, K. B., Ramachandran, V., Sung, B., Chakraborty, A., Bresalier, R. S., Logsdon, C., Aggarwal, B. B., Krishnan, S., & Guha, S. (2008). Neutrophil Gelatinase-Associated Lipocalin: A Novel Suppressor of Invasion and Angiogenesis in Pancreatic Cancer. *Cancer Research*, 68(15), 6100–6108. <https://doi.org/10.1158/0008-5472.CAN-08-0540>

Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017). Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. *Journal of the American Society of Nephrology : JASN*, 28(4), 1023–1039. <https://doi.org/10.1681/ASN.2016060666>

Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., Boer, I. H. de, Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., Neumiller, J. J., Patel, U. D., Ratner, R. E., Whaley-Connell, A. T., & Molitch, M. E. (2014). Diabetic Kidney Disease: A Report From an ADA Consensus Conference. *American Journal of Kidney Diseases*, 64(4), 510–533. <https://doi.org/10.1053/j.ajkd.2014.08.001>

1, K., & Lewis, J. B. (2018). Update on Diabetic Nephropathy: Core curriculum 2018. *American Journal of Kidney Diseases: The Official*



- Journal of the National Kidney Foundation, 71(6), 884–895.
<https://doi.org/10.1053/j.ajkd.2017.10.026>
- Vallon, V., & Komers, R. (2011). Pathophysiology of the Diabetic Kidney. *Comprehensive Physiology*, 1(3), 1175–1232.
<https://doi.org/10.1002/cphy.c100049>
- Varghese, R. T., & Jialal, I. (2023). Diabetic Nephropathy. In StatPearls. StatPearls Publishing.
<http://www.ncbi.nlm.nih.gov/books/NBK534200/>
- Yang, J., Goetz, D., Li, J. Y., Wang, W., Mori, K., Setlik, D., Du, T., Erdjument-Bromage, H., Tempst, P., Strong, R., & Barasch, J. (2002). An iron delivery pathway mediated by a lipocalin. *Molecular Cell*, 10(5), 1045–1056. [https://doi.org/10.1016/s1097-2765\(02\)00710-4](https://doi.org/10.1016/s1097-2765(02)00710-4)
- Yang, X. O., Chang, S. H., Park, H., Nurieva, R., Shah, B., Acero, L., Wang, Y.-H., Schluns, K. S., Broaddus, R. R., Zhu, Z., & Dong, C. (2008). Regulation of inflammatory responses by IL-17F. *The Journal of Experimental Medicine*, 205(5), 1063–1075.
<https://doi.org/10.1084/jem.20071978>
- Yuen, L., & Wong, V. W. (2015). Gestational diabetes mellitus: Challenges for different ethnic groups. *World Journal of Diabetes*, 6(8), 1024–1032. <https://doi.org/10.4239/wjd.v6.i8.1024>
- Zhang, X. X., Kong, J. and Yun, K. (2020) ‘Prevalence of Diabetic Nephropathy among Patients with Type 2 Diabetes Mellitus in China: A Meta-Analysis of Observational Studies’, *Journal of Diabetes Research*, 2020. doi: 10.1155/2020/2315607.

